China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its in-house developed IL-11 monoclonal antibody (mAb), 9MW3811. The drug is intended for the treatment of various advanced malignant tumors and fibrotic diseases.
Therapeutic Potential of 9MW3811 in Fibrosis and Tumors
9MW3811 has demonstrated the ability to effectively block the activation of the downstream signal pathway of IL-11, which contributes to its therapeutic effects on fibrosis and tumors. Research indicates that IL-11 is up-regulated in invasive lung fibroblasts of patients with idiopathic pulmonary fibrosis, and it plays a role in tumorigenesis, including cell proliferation, angiogenesis, and cell apoptosis.
Combination Therapy with Anti-PD-1 Antibodies and Preclinical Success
Studies based on multiple solid tumor models have shown that the combination of 9MW3811 and anti-PD-1 antibodies can achieve effective anti-tumor treatment effects. In preclinical studies for fibrotic diseases, 9MW3811 significantly reduced the area of pulmonary fibrosis, decreased lung collagen content, and improved lung function in fibrosis model mice.
Clinical Trial Approval in Australia and Safety Profile
The drug obtained clinical trial approval in Australia in February of this year, with periodic data indicating a good safety profile. This development highlights the potential of 9MW3811 as a promising therapeutic option for patients with fibrotic diseases and various advanced malignant tumors.-Fineline Info & Tech
